Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024

コンパニオン診断の世界市場予測:アッセイ、キット、ソフトウェア及びサービス

◆タイトル:Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024
◆商品コード:MD 5463
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年9月16日
◆ページ数:240
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、コンパニオン診断の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品及びサービス別(アッセイ、キット、ソフトウェア及びサービス)分析、技術別(PCR、NGS、ISH、IHC)分析、疾患別(乳がん、肺がん、結腸直腸がん、心血管疾患)分析、エンドユーザー別(製薬会社、CRO)分析、コンパニオン診断の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。MarketsandMarkets社は、コンパニオン診断の世界市場規模が2019年35億ドルから2024年73億ドルまで年平均15.7%成長すると予測しています。

“The companion diagnostics market is estimated to grow at a CAGR of 15.7%”The companion diagnostics market is projected to reach 7.3 billion by 2024 from USD 3.5 billion in 2019, at a CAGR of 15.7%. The growth of the companion diagnostics industry is tied primarily to its various advantages, the growing need for targeted therapy, the increasing importance of personalized medicine. Moreover, the increasing global incidence of cancer, ever-increasing application areas of companion diagnostics, rising demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the increasing number of clinical trials are expected to present growth opportunities for players in the market. However, the high cost of companion diagnostic tests and the uncertain reimbursement scenario in different regions affect market growth to a certain extent during the forecast period.

“Cancer segment to witness the highest growth during the forecast period”
The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research.

“Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user”
The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

“APAC market to witness the highest growth during the forecast period”
Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

A breakdown of the primary participants in this report is provided below:
• By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation: C-level–35%, Director Level–25%, and Others–40%
• By Region: North America–45%, Europe–20%, Asia Pacific–30%, Rest of the World (RoW)–5%

The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), and Guardant Health, Inc. (US).

Research Coverage:
This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
• Market Development: Comprehensive information on the lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
• Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market

【レポートの目次】

1 Introduction (Page No. – 21)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 25)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 34)
4 Premium Insights (Page No. – 39)
4.1 Companion Diagnostics: Market Overview
4.2 Asia Pacific: Companion Diagnostics Market, By End User (2018)
4.3 Regional Mix: Companion Diagnostics Market
4.4 Companion Diagnostics Market: Developing vs. Developed Countries
4.5 Geographical Snapshot of the Companion Diagnostics Market
5 Market Overview (Page No. – 43)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Advantages of Companion Diagnostics
5.2.1.2 Growing Need for Targeted therapy
5.2.1.3 Growing Importance of Personalized Medicine
5.2.1.4 Increasing Global Incidence of Cancer
5.2.1.5 Growing Application Areas of Companion Diagnostics
5.2.2 Restraints
5.2.2.1 High Cost of Companion Diagnostic Tests
5.2.2.2 Uncertain Reimbursement Scenario in Different Regions
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Next-Generation Sequencing
5.2.3.2 Growing Significance of Companion Diagnostics in Drug Development
5.2.3.3 Increasing Number of Clinical Trials
5.2.4 Challenges
5.2.4.1 Shortage of Trained Professionals
6 Industry Insights (Page No. – 52)
6.1 Introduction
6.2 Industry Trends
6.2.1 Growing Focus on Liquid Biopsy in Companion Diagnostics
6.2.2 Increasing Collaborations
6.3 Regulatory Analysis
6.3.1 North America
6.3.1.1 US
6.3.1.2 Canada
6.3.2 Europe
6.3.3 Asia Pacific
6.3.3.1 Australia
6.3.3.2 Japan
6.3.3.3 China
6.3.3.4 India
6.3.4 Brazil
6.4 Product Pipeline Analysis
7 Companion Diagnostics Market, By Product & Service (Page No. – 63)
7.1 Introduction
7.2 Assays, Kits, & Reagents
7.2.1 The Volume of Cdx Tests Performed in Laboratories is Increasing, Which Supports the Adoption of Assays & Kits
7.3 Software & Services
7.3.1 The Need for Effective Data Management Software Within Laboratories is Increasing, Contributing to the Growth of the Companion Diagnostic Software & Services Market
8 Companion Diagnostics Market, By Technology (Page No. – 68)
8.1 Introduction
8.2 Polymerase Chain Reaction (PCR)
8.2.1 Growing Applications of PCR Technologies in the Field of Personalized Medicine and Companion Diagnostics Drive the Growth of This Segment
8.3 Next-Generation Sequencing (NGS)
8.3.1 The NGS Segment is Expected to Grow at the Highest CAGR During the Forecast Period
8.4 in Situ Hybridization (ISH)
8.4.1 Increasing Adoption of ISH is Mainly Due to Advancements in Hybridization and Its Demand in Small-Tumor Diagnostics
8.5 Immunohistochemistry (IHC)
8.5.1 Increasing Demand for User-Friendly and Cost-Effective Technologies in Companion Diagnostics to Drive the Growth of This Segment
8.6 Other Technologies
9 Companion Diagnostics Market, By Indication (Page No. – 80)
9.1 Introduction
9.2 Cancer
9.2.1 Breast Cancer
9.2.1.1 Breast Cancer is the Most Common Cancer Among Women—A Key Factor Contributing to the Large Share of This Market Segment
9.2.2 Lung Cancer
9.2.2.1 Growing Demand for Therapeutic Drugs and their High Efficacy in the Treatment of Lung Cancer Increase the Adoption of Companion Diagnostics in This Segment
9.2.3 Colorectal Cancer
9.2.3.1 Growing Need for Molecular Profiling of Primary Tumors in Colorectal Cancer to Drive Growth in This Market Segment
9.2.4 Melanoma
9.2.4.1 Growing Incidence of Melanoma, Along With the Need for the Early Diagnosis of Genetic-Mutated Tumors, Drives the Demand for Companion Diagnostics
9.2.5 Gastric Cancer
9.2.5.1 Increasing Focus of Market Players on the Development of Tests and Kits for Gastric Cancer Indications to Drive Market Growth
9.3 Neurological Diseases
9.3.1 Growing Number of Diagnostic Technologies for the Treatment of Neurological Diseases to Boost the Adoption of Companion Diagnostics in This Segment
9.4 Infectious Diseases
9.4.1 Growing Focus of Companion Diagnostic Players on Orphan Indications to Propel the Growth of This Segment During
9.5 Cardiovascular Diseases
9.5.1 Growing Demand for Targeted Therapies Due to High Incidence and Mortality Rate of Cardiovascular Diseases to Drive Growth in This Segment
9.6 Other Indications
10 Companion Diagnostics Market, By End User (Page No. – 98)
10.1 Introduction
10.2 Pharmaceutical & Biopharmaceutical Companies
10.2.1 Wide Usage of Companion Diagnostics in Pharmaceutical & Biopharmaceutical Companies Owing to their Growing Prominence in Drug Development to Drive Market Growth
10.3 Reference Laboratories
10.3.1 Growing Incidence of Diseases Such as Cancer and the Rising Demand for Targeted Therapies to Drive the Growth of This End-User Segment
10.4 Contract Research Organizations
10.4.1 Cros Offer A Complete Range of Companion Diagnostic Services Ranging From Companion Diagnostic Development to Targeted Therapy-Related Clinical Trials
10.5 Other End Users
11 Companion Diagnostics Market, By Region (Page No. – 105)
11.1 Introduction
11.2 North America
11.2.1 US
11.2.1.1 The US is the Largest Market for Companion Diagnostics in North America
11.2.2 Canada
11.2.2.1 Government Initiatives to Promote Companion Diagnostics in Various Indications are Expected to Drive Market Growth in Canada
11.3 Europe
11.3.1 Germany
11.3.1.1 Germany is A Major Market for Pharmaceutical and Biotechnology Products in Europe
11.3.2 UK
11.3.2.1 Growth in the Country’s Life Science Industry and Increasing Research are Key Factors Driving Market Growth in the UK
11.3.3 Switzerland
11.3.3.1 Switzerland Boasts A Strong Research-Oriented Pharma Industry, A Key Factor Supporting Market Growth
11.3.4 France
11.3.4.1 Increasing Government Funding for Genomics and Personalized Therapeutics R&D is Driving Market Growth
11.3.5 Italy
11.3.5.1 Growing Disease Prevalence has Contributed to the Demand for Better, More Powerful Therapeutics in Italy
11.3.6 Spain
11.3.6.1 Medical Institutes in Spain are Increasingly Focusing on Cancer Biomarker Research
11.3.7 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.1.1 Japan Holds the Largest Share of the Market in APAC
11.4.2 China
11.4.2.1 China is One of the Most Prominent Research Markets, Worldwide
11.4.3 India
11.4.3.1 Initiatives By the Indian Government to Tackle the Growing Burden of Cancer are Expected to Increase the Adoption of Companion Diagnostics in the Country
11.4.4 Australia
11.4.4.1 Growing Geriatric Population in Australia has Resulted in Initiatives to Enhance Healthcare Access and Infrastructure
11.4.5 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.1.1 Brazil Dominates the Latin American Companion Diagnostics Market
11.5.2 Mexico
11.5.2.1 Mexico is Emerging as A Prominent Medical Tourism Hub
11.5.3 Rest of Latin America
11.6 Middle East & Africa
11.6.1 Rising Cancer Incidence Rate has Attracted Stakeholder Attention to Regional Markets in MEA
12 Competitive Landscape (Page No. – 186)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Leadership Mapping, 2018
12.4 Vendor Inclusion Criteria
12.5 Vendor Dive
12.5.1 Visionary Leaders
12.5.2 Innovators
12.5.3 Emerging Companies
12.5.4 Dynamic Differentiators
12.6 Competitive Situations and Trends
12.6.1 Partnerships, Collaborations, & Agreements
12.6.2 Acquisitions
13 Company Profiles (Page No. – 196)
(Business Overview, Products and Services Offered, Recent Developments, MnM View)*
13.1 F. Hoffmann-La Roche AG
13.2 Agilent Technologies, Inc.
13.3 QIAGEN N.V.
13.4 Abbott Laboratories, Inc.
13.5 Almac Group
13.6 Danaher Corporation
13.7 Illumina Inc.
13.8 Biomérieux SA
13.9 Myriad Genetics, Inc.
13.10 Sysmex Corporation
13.11 Thermo Fisher Scientific, Inc.
13.12 Abnova Corporation
13.13 Guardant Health, Inc.
*Business Overview, Products and Services Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.
14 Appendix (Page No. – 230)
14.1 Insights From Industry Experts
14.2 Discussion Guide
14.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.4 Available Customizations
14.5 Related Reports
14.6 Author Details

List of Tables (176 Tables)
Table 1 Standard Currency Conversion Rates
Table 2 Companion Diagnostics Market Snapshot, 2019 vs. 2024
Table 3 Companion Diagnostics Reimbursement Scenario Worldwide
Table 4 Partnerships & Collaborations for Developing NGS-Based Companion Diagnostic Tests
Table 5 List of Clinical Trials for Companion Diagnostics
Table 6 Recent Collaborations in the Companion Diagnostics Market
Table 7 US: Classification of Medical Devices
Table 8 Japan: Classification of Medical Devices
Table 9 China: Time, Cost, and Complexity of Registration Process
Table 10 India: Time, Cost, and Complexity of Registration Process
Table 11 Companion Diagnostics Product Pipeline Analysis, By Market Player: Current Market Scenario
Table 12 Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 13 Companion Diagnostics Market for Assays, Kits, & Reagents, By Country, 2017–2024 (USD Million)
Table 14 Companion Diagnostics Market for Software & Services, By Country, 2017–2024 (USD Million)
Table 15 Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 16 Comparison of Tissue Sequencing Platforms for the Detection of Ras/Braf Mutation
Table 17 Major PCR Tests/Kits Available in the Market
Table 18 Companion Diagnostics Market for Polymerase Chain Reaction, By Country, 2017–2024 (USD Million)
Table 19 Major NGS Tests/Kits Available in the Market
Table 20 Companion Diagnostics Market for Next-Generation Sequencing, By Country, 2017–2024 (USD Million)
Table 21 Major ISH Tests/Kits Available in the Market
Table 22 Companion Diagnostics Market for in Situ Hybridization, By Country, 2017–2024 (USD Million)
Table 23 Major IHC Tests/Kits Available in the Market
Table 24 Companion Diagnostics Market for Immunohistochemistry, By Country, 2017–2024 (USD Million)
Table 25 Companion Diagnostics Market for Other Technologies, By Country, 2017–2024 (USD Million)
Table 26 Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 27 Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 28 Companion Diagnostics Market for Cancer, By Country, 2017–2024 (USD Million)
Table 29 Companion Diagnostics Market for Breast Cancer, By Country, 2017–2024 (USD Million)
Table 30 Companion Diagnostics Market for Lung Cancer, By Country, 2017–2024 (USD Million)
Table 31 Companion Diagnostics Market for Colorectal Cancer, By Country, 2017–2024 (USD Million)
Table 32 Companion Diagnostics Market for Melanoma, By Country, 2017–2024 (USD Million)
Table 33 Companion Diagnostics Market for Gastric Cancer, By Country, 2017–2024 (USD Million)
Table 34 Companion Diagnostics Market for Neurological Diseases, By Country, 2017–2024 (USD Million)
Table 35 Companion Diagnostics Market for Infectious Diseases, By Country, 2017–2024 (USD Million)
Table 36 Companion Diagnostics Market for Cardiovascular Diseases, By Country, 2017–2024 (USD Million)
Table 37 Companion Diagnostics Market for Other Indications, By Country, 2017–2024 (USD Million)
Table 38 Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 39 Companion Diagnostics Market for Pharmaceutical & Biopharmaceutical Companies, By Country, 2017–2024 (USD Million)
Table 40 Companion Diagnostics Market for Reference Laboratories, By Country, 2017–2024 (USD Million)
Table 41 Companion Diagnostics Market for Contract Research Organizations, By Country, 2017–2024 (USD Million)
Table 42 Companion Diagnostics Market for Other End Users, By Country, 2017–2024 (USD Million)
Table 43 Companion Diagnostics Market, By Region, 2017–2024 (USD Million)
Table 44 North America: Companion Diagnostics Market, By Country, 2017–2024 (USD Million)
Table 45 North America: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 46 North America: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 47 North America: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 48 North America: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 49 North America: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 50 US: Key Macroindicators
Table 51 US: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 52 US: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 53 US: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 54 US: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 55 US: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 56 Canada: Key Macroindicators
Table 57 Canada: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 58 Canada: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 59 Canada: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 60 Canada: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 61 Canada: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 62 Europe: Companion Diagnostics Market, By Country, 2017–2024 (USD Million)
Table 63 Europe: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 64 Europe: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 65 Europe: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 66 Europe: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 67 Europe: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 68 Germany: Key Macroindicators
Table 69 Germany: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 70 Germany: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 71 Germany: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 72 Germany: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 73 Germany: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 74 UK: Key Macroindicators
Table 75 UK: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 76 UK: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 77 UK: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 78 UK: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 79 UK: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 80 Switzerland: Key Macroindicators
Table 81 Switzerland: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 82 Switzerland: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 83 Switzerland: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 84 Switzerland: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 85 Switzerland: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 86 France: Key Macroindicators
Table 87 France: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 88 France: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 89 France: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 90 France: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 91 France: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 92 Italy: Key Macroindicators
Table 93 Italy: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 94 Italy: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 95 Italy: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 96 Italy: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 97 Italy: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 98 Spain: Key Macroindicators
Table 99 Spain: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 100 Spain: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 101 Spain: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 102 Spain: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 103 Spain: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 104 RoE: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 105 RoE: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 106 RoE: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 107 RoE: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 108 RoE: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 109 APAC: Companion Diagnostics Market, By Country, 2017–2024 (USD Million)
Table 110 APAC: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 111 APAC: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 112 APAC: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 113 APAC: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 114 APAC: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 115 Japan: Key Macroindicators
Table 116 Japan: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 117 Japan: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 118 Japan: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 119 Japan: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 120 Japan: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 121 China: Key Macroindicators
Table 122 China: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 123 China: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 124 China: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 125 China: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 126 China: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 127 India: Key Macroindicators
Table 128 India: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 129 India: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 130 India: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 131 India: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 132 India: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 133 Australia: Key Macroindicators
Table 134 Australia: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 135 Australia: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 136 Australia: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 137 Australia: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 138 Australia: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 139 RoAPAC: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 140 RoAPAC: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 141 RoAPAC: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 142 RoAPAC: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 143 RoAPAC: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 144 Latin America: Companion Diagnostics Market, By Country, 2017–2024 (USD Million)
Table 145 Latin America: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 146 Latin America: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 147 Latin America: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 148 Latin America: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 149 Latin America: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 150 Brazil: Key Macroindicators
Table 151 Brazil: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 152 Brazil: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 153 Brazil: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 154 Brazil: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 155 Brazil: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 156 Mexico: Key Macroindicators
Table 157 Mexico: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 158 Mexico: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 159 Mexico: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 160 Mexico: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 161 Mexico: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 162 Rola: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 163 Rola: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 164 Rola: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 165 Rola: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 166 Rola: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 167 MEA: Companion Diagnostics Market, By Product & Service, 2017–2024 (USD Million)
Table 168 MEA: Companion Diagnostics Market, By Technology, 2017–2024 (USD Million)
Table 169 MEA: Companion Diagnostics Market, By Indication, 2017–2024 (USD Million)
Table 170 MEA: Companion Diagnostics Market for Cancer, By Type, 2017–2024 (USD Million)
Table 171 MEA: Companion Diagnostics Market, By End User, 2017–2024 (USD Million)
Table 172 Growth Strategy Matrix (2016–2019)
Table 173 Product Launches & Approvals, 2016–2019
Table 174 Partnerships, Collaborations, & Agreements, 2016–2019
Table 175 Acquisitions, 2016–2019
Table 176 Expansions, 2016-2019

List of Figures (46 Figures)
Figure 1 Research Design
Figure 2 Primary Sources
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market Size Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Companion Diagnostics Market, By Product & Service, 2019 vs. 2024 (USD Million)
Figure 8 Companion Diagnostics Market, By Technology, 2019 vs. 2024 (USD Million)
Figure 9 Companion Diagnostics Market, By Indication, 2019 vs. 2024 (USD Million)
Figure 10 Companion Diagnostics Market, By End User, 2019 vs. 2024 (USD Million)
Figure 11 Geographical Snapshot of the Companion Diagnostics Market
Figure 12 Increasing Demand for Targeted Therapies and Personalized Medicine in the Pharmaceutical Industry is Driving Market Growth
Figure 13 Pharmaceutical & Biopharmaceutical Companies Commanded the Largest Share of the APAC Companion Diagnostics Market in 2018
Figure 14 Asia Pacific to Witness the Highest Growth in the Forecast Period
Figure 15 Developing Countries to Register Higher Growth During the Forecast Period
Figure 16 China to Grow at the Highest CAGR During the Forecast Period
Figure 17 Companion Diagnostics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 18 Global Launch of Personalized Medicine Products, 2008–2016
Figure 19 Global Cancer Incidence, 2008–2030
Figure 20 Premarket Notification: 510(K) Approval for Companion Diagnostic Products
Figure 21 India: Regulatory Process for Ivd Devices
Figure 22 Assays, Kits, & Reagents to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 23 Polymerase Chain Reaction to Dominate the Companion Diagnostics Technology Market During the Forecast Period
Figure 24 Cancer Indication Segment to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 25 Breast Cancer to Dominate the Companion Diagnostics Market for Cancer During the Forecast Period
Figure 26 Global Lung Cancer Incidence, 2012–2030
Figure 27 Pharmaceutical& Biopharmaceutical Companies to Dominate the Companion Diagnostics Market During the Forecast Period
Figure 28 Geographic Snapshot: China is Expected to Grow at the Highest CAGR During the Forecast Period
Figure 29 North America: Companion Diagnostics Market Snapshot
Figure 30 Europe: Companion Diagnostics Market Snapshot
Figure 31 Asia Pacific: Companion Diagnostics Market Snapshot
Figure 32 Key Developments in the Companion Diagnostics Market Between January 2016 and May 2019
Figure 33 Companion Diagnostics Market Share Analysis, By Key Player, 2018
Figure 34 Companion Diagnostics Market Competitive Leadership Mapping, 2018
Figure 35 Product Launches & Approvals Was the Key Growth Strategy Adopted By Major Players Between 2016 & 2019
Figure 36 F. Hoffmann-La Roche Ag: Company Snapshot
Figure 37 Agilent Technologies, Inc.: Company Snapshot
Figure 38 QIAGEN N.V.: Company Snapshot
Figure 39 Abbott Laboratories, Inc.: Company Snapshot
Figure 40 Danaher Corporation: Company Snapshot
Figure 41 Illumina Inc.: Company Snapshot
Figure 42 Biomérieux SA: Company Snapshot
Figure 43 Myriad Genetics, Inc.: Company Snapshot
Figure 44 Sysmex Corporation: Company Snapshot
Figure 45 Thermo Fisher Scientific: Company Snapshot
Figure 46 Guardant Health, Inc.: Company Snapshot

★調査レポート[コンパニオン診断の世界市場予測:アッセイ、キット、ソフトウェア及びサービス] ( Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024 / MD 5463) 販売に関する免責事項
[コンパニオン診断の世界市場予測:アッセイ、キット、ソフトウェア及びサービス] ( Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2024 / MD 5463) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆